BEGIN:VCALENDAR
VERSION:2.0
PRODID:talks.ox.ac.uk
BEGIN:VEVENT
SUMMARY:Why Were the Checkpoint Inhibitors Developed into Drugs? - Dr Dona
 ld Drakeman (Distinguished Research Professor\, University of Notre Dame (
 US)\, and Fellow\, Operations and Technology Management\, Cambridge Judge 
 Business School)
DTSTART;VALUE=DATE-TIME:20201026T120000Z
DTEND;VALUE=DATE-TIME:20201026T130000Z
UID:https://talks.ox.ac.uk/talks/id/b8654080-0f80-4c08-9c8d-f6f89373d585/
DESCRIPTION:The 2018 Nobel Prize announcement recognized the discovery of 
 the “entirely new principle for cancer therapy” of negative immune reg
 ulation.  It also cited the pharmaceutical industry’s lack of interest. 
  Ultimately\, a small biotech company developed both the anti-CTLA-4 antib
 ody Yervoy/ipilimumab\, based on James Allison’s work\, and the anti-PD-
 1 antibody Opdivo/nivolumab based on Tasuku Honjo’s work. This talk will
  discuss why pharmaceutical companies were not interested\, why these prod
 ucts were developed by the biotech company Medarex\, and how this example 
 highlights the results of new research into the origins of the most innova
 tive medicines of the past two decades.\nSpeakers:\nDr Donald Drakeman (Di
 stinguished Research Professor\, University of Notre Dame (US)\, and Fello
 w\, Operations and Technology Management\, Cambridge Judge Business School
 )
LOCATION:Kennedy Institute of Rheumatology (This seminar will be held usin
 g Zoom. Please register here: https://zoom.us/meeting/register/tJIkdO-rqzw
 sGtyGKaCW65anWJqcYkaCXzRC )\, Headington OX3 7FY
TZID:Europe/London
URL:https://talks.ox.ac.uk/talks/id/b8654080-0f80-4c08-9c8d-f6f89373d585/
BEGIN:VALARM
ACTION:display
DESCRIPTION:Talk:Why Were the Checkpoint Inhibitors Developed into Drugs? 
 - Dr Donald Drakeman (Distinguished Research Professor\, University of Not
 re Dame (US)\, and Fellow\, Operations and Technology Management\, Cambrid
 ge Judge Business School)
TRIGGER:-PT1H
END:VALARM
END:VEVENT
END:VCALENDAR